Kymera Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KYMR research report →
Companywww.kymeratx.com
Kymera Therapeutics, Inc. , a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
- CEO
- Nello Mainolfi
- IPO
- 2020
- Employees
- 208
- HQ
- Watertown, MA, US
Price Chart
Valuation
- Market Cap
- $6.63B
- P/E
- -24.97
- P/S
- 128.90
- P/B
- 5.11
- EV/EBITDA
- -21.47
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -697.81%
- Net Margin
- -612.17%
- ROE
- -25.02%
- ROIC
- -22.17%
Growth & Income
- Revenue
- $39.20M · -16.72%
- Net Income
- $-311,400,000 · -39.11%
- EPS
- $-3.69 · -23.83%
- Op Income
- $-349,400,000
- FCF YoY
- -13.02%
Performance & Tape
- 52W High
- $103.00
- 52W Low
- $28.06
- 50D MA
- $83.27
- 200D MA
- $69.50
- Beta
- 2.06
- Avg Volume
- 628.70K
Get TickerSpark's AI analysis on KYMR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 19, 26 | Esposito Pamela | other | 1,000 |
| May 19, 26 | Esposito Pamela | other | 1,000 |
| May 18, 26 | Jacobs Bruce N. | other | 15,000 |
| May 18, 26 | Jacobs Bruce N. | other | 15,000 |
| May 11, 26 | Ridloff Elena | other | 3,000 |
| May 11, 26 | Ridloff Elena | other | 3,000 |
| May 11, 26 | Ridloff Elena | sell | 3,000 |
| Apr 29, 26 | Mainolfi Nello | other | 30,000 |
| Apr 29, 26 | Mainolfi Nello | sell | 17,005 |
| Apr 29, 26 | Mainolfi Nello | sell | 12,059 |
Our KYMR Coverage
We haven't published any research on KYMR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KYMR Report →